Price Target Update on Merck & Company (NYSE:MRK)

Merck & Company (NYSE:MRK) : 12 investment research analysts covering Merck & Company (NYSE:MRK) have an average price target of $62.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $53 for the short term. Analysts expect the variance to be within $8.1 of the average price.

Other Equity analysts have also commented on the company shares. Brokerage firm Jefferies maintains its rating on Merck & Company (NYSE:MRK). As per the latest information, the brokerage house lowers the price target to $53 per share from a prior target of $54. The shares have been rated Hold. The rating by the firm was issued on June 14, 2016.

Merck & Company (NYSE:MRK): stock turned positive on Thursday. Though the stock opened at $57.48, the bulls momentum made the stock top out at $57.68 level for the day. The stock recorded a low of $57.105 and closed the trading day at $57.68, in the green by 1.12%. The total traded volume for the day was 6,968,390. The stock had closed at $57.04 in the previous days trading.

The company shares have dropped -1.49% from its 1 Year high price. On Aug 19, 2015, the shares registered one year high at $60.07 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $55.71 and the 200 Day Moving Average price is recorded at $53.38. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Golestani Clark, officer (EVP & Chief Info Officer) of Merck & Co., Inc., had unloaded 39,877 shares at an average price of $54.67 in a transaction dated on May 19, 2016. The total value of the transaction was worth $2,180,076.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.